14-day Premium Trial Subscription Sign Up For FreeGet Free

Affimed N.V. Stock Forecast NASDAQ:AFMD

Price Target and Analyst Ratings

Most Recent Rating

BMO Capital Markets is very positive about AFMD and gave it a "Positive - Outperform" rating on April 12, 2021. The price target was changed from $12.00 to $15.00.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-04-18 Buy Reiterated by SVB Leerink $9.51
2021-04-12 Positive - Outperform Target Raised by BMO Capital Markets $9.65 $12.00 → $15.00
2021-03-30 Outperform Initiated by Credit Suisse Group $7.34
2021-03-30 Overweight Target Raised by Wells Fargo & Company $7.34 $10.00 → $15.00
2021-03-24 Overweight - Overweight Target Raised by Wells Fargo & Company $7.78 $10.00 → $15.00
2021-03-24 Overweight - Positive Target Raised by Wells Fargo & Company $7.78 $10.00 → $15.00
2021-03-17 Outperform Target Raised by SVB Leerink $8.38 $9.00 → $14.00
2021-03-11 Outperform Target Raised by SVB Leerink $7.54 $9.00 → $14.00
2020-11-11 Outperform Target Raised by SVB Leerink $4.44 $8.00 → $9.00
2020-08-09 Market Perform - Buy Reiterated by Laidlaw $3.81 $10.00
2020-06-24 Outperform Target Raised by SVB Leerink $4.09 $7.00 → $8.00

AFMD Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -19.43% during the next 3 months and, with a 90% probability hold a price between $4.06 and $5.53 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-20 $5.01 $5.93 $6.84
2021-09-21 $4.99 $5.90 $6.82
2021-09-22 $4.96 $5.88 $6.79
2021-09-23 $4.94 $5.85 $6.76
2021-09-24 $4.91 $5.82 $6.74
2021-09-27 $4.88 $5.80 $6.71
2021-09-28 $4.86 $5.77 $6.68
2021-09-29 $4.83 $5.74 $6.66
2021-09-30 $4.80 $5.72 $6.63
2021-10-01 $4.78 $5.69 $6.61
2021-10-04 $4.75 $5.67 $6.58
2021-10-05 $4.72 $5.64 $6.55
2021-10-06 $4.70 $5.61 $6.53
2021-10-07 $4.67 $5.59 $6.50
2021-10-08 $4.65 $5.56 $6.47
2021-10-11 $4.62 $5.53 $6.45
2021-10-12 $4.59 $5.51 $6.42
2021-10-13 $4.57 $5.48 $6.39
2021-10-14 $4.54 $5.45 $6.37
2021-10-15 $4.51 $5.43 $6.34
2021-10-18 $4.49 $5.40 $6.32
2021-10-19 $4.46 $5.38 $6.29
2021-10-20 $4.44 $5.35 $6.26
2021-10-21 $4.41 $5.32 $6.24
2021-10-22 $4.38 $5.30 $6.21
2021-10-25 $4.36 $5.27 $6.18
2021-10-26 $4.33 $5.24 $6.16
2021-10-27 $4.30 $5.22 $6.13
2021-10-28 $4.28 $5.19 $6.11
2021-10-29 $4.25 $5.17 $6.08

About Affimed N.V.

Affimed NV Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company’s product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, in... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT